| Literature DB >> 32815062 |
Asieh Heirani-Tabasi1, Mahdi Mirahmadi1, Mohammad Amir Mishan2, Hojjat Naderi-Meshkin1, Shirin Toosi1, Maryam M Matin1,3,4, Hamid Reza Bidkhori1, Ahmad Reza Bahrami5,6,7.
Abstract
Adipose-derived mesenchymal stem cells (Ad-MSCs) have been designated as the promising agents for clinical applications for easy accessibility, multi-linage differentiation and immunomodulation capacity. Despite this, optimal cell delivery conditions have remained as a clinical challenge and improvement of stem cell homing to the target organs is being considered as a major strategy in cell therapy systemic injection. It has been shown that homing of mesenchymal stem cells are increased when treated with physical or chemical hypoxia-mimicking factors, however, efficiency of different agents remained to be determined. In this study, hypoxia-mimicking agents, including valproic acid (VPA), cobalt chloride (CoCl2) and deferoxamine (DFX) were examined to determine whether they are able to activate signaling molecules involved in migration of Ad-MSCs in vitro. We report that Ad-MSCs treated by DFX resulted in a significantly enhanced mRNA expression of MAPK4 (associated with MAPK signaling pathway), INPP4B (associated with Inositol polyphosphate pathway), VEGF-A and VEGF-C (associated with cytokine-cytokine receptor pathways), IL-8 and its receptor, CXCR2 (associated with IL-8 signaling pathway). While the cells treated with VPA did not show such effects and CoCl2 only upregulated VEGF-A and VEGF-C gene expression. Furthermore, results of wound-healing assays showed migration capacity of Ad-MSCs treated with DFX significantly increased 8 and 24 h of the treatment. This study provides credible evidence around DFX, which might be an effective drug for pharmacological preconditioning of Ad-MSCs to boost their homing capacity and regeneration of damaged tissues though, activation of the migration-related signaling pathways.Entities:
Keywords: Adipose derived mesenchymal stem cells; Cell- and tissue-based therapy; Deferoxamine; Interleukin-8; Signal transduction
Mesh:
Substances:
Year: 2020 PMID: 32815062 DOI: 10.1007/s10561-020-09851-2
Source DB: PubMed Journal: Cell Tissue Bank ISSN: 1389-9333 Impact factor: 1.522